Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

Massachusetts General Hospital Cancer Center, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Boston, MA
Treatments:Biologic therapyHospital:Massachusetts General Hospital Cancer Center
Drugs:Journal:Link
Date:Jan 2012

Description:

Patients:
This phase 3 study involved 716 men with castration-resistant prostate cancer. The median patient age was 74 years.

Treatment:
Patients were treated with the biologic therapy agent denosumab, which is a monoclonal antibody that inactivates a protein called RANKL and subsequently works to prevent bone metastases commonly associated with prostate cancer.

Toxicities:
Treatment-related deaths were reported, but specific causes were not given. Severe anemia, urinary tract infection, and loss of bone density were reported.

Results:
The reported median overall survival was 43.9 months.

Support:
This study was supported by Amgen, makers of denosumab.

Correspondence: Dr. Matthew R Smith; email: smith.matthew@mgh.harvard.edu



Back